ANI Pharma (ANIP) Q3 2026 Earnings Call Transcript
ANI Pharma (ANIP) reported Q3 2026 revenue of $290.8M, up 28% YoY, with adjusted EBITDA of $82.3M, up 40% YoY. Rare disease revenues grew 36% YoY, while generics grew 11%. The company revised Cortrophin Gel revenue guidance to $480M-$500M for 2026, down from $520M-$540M, citing supply chain issues. ANIP also announced an offer to acquire Aegidus Therapeutics, aiming to expand its rare disease portfolio.
How this was made
The 30-second read
Why it matters
The earnings beat and acquisition provide fresh catalysts, while the Cortrophin guidance reduction introduces a near‑term downside risk.
Market read
First‑time disclosure of earnings, guidance changes, and acquisition makes the article highly relevant for traders.
What to watch
Potential integration challenges with Aegidus and the timing of emcetate launch may delay expected upside.
Background
ANI Pharma presented its Q3 2026 earnings, updated guidance, and disclosed a strategic acquisition of Aegidus Therapeutics.
Ticker impact
Q3 2026 earnings call disclosed $290.8M revenue, revised Cortrophin guidance, and announced offer to acquire Aegidus Therapeutics.
mixed pressure as the market weighs higher overall guidance against the Cortrophin guidance cut.
New earnings numbers and acquisition offer are primary disclosures; the guidance revision is material and likely to move the stock immediately.
Market effects
Rare‑disease and generics sectors may see increased investor interest from ANI's acquisition strategy.
U.S. biotech market could experience modest re‑rating as ANI expands its rare‑disease pipeline.
Limited to biotech investors; no broad macro impact.
Counterpoint
The Cortrophin guidance cut could signal execution risk, suggesting a short‑term pullback despite overall growth.
Key entities
- CompanyANI Pharma
U.S. biotech firm reporting Q3 results and acquisition.
- CompanyAegidus Therapeutics
Target of ANI's acquisition to expand rare‑disease portfolio.
